Experimental and Applied Immunotherapy
Experimental and Applied Immunotherapy

Author: Jeffrey Medin

Publisher: Springer Science & Business Media

Published: 2010-12-03

Total Pages: 447

ISBN-13: 1607619806

DOWNLOAD EBOOK

Immunotherapy is now recognized as an essential component of treatment for a wide variety of cancers. It is an interdisciplinary field that is critically dependent upon an improved understanding of a vast network of cross-regulatory cellular populations and a diversity of molecular effectors; it is a leading example of translational medicine with a favorable concept-to-clinical-trial timeframe of just a few years. There are many established immunotherapies already in existence, but there are exciting new cancer immunotherapies just on the horizon, which are likely to be more potent, less toxic and more cost effective than many therapies currently in use. Experimental and Applied Immunotherapy is a state-of-the-art text offering a roadmap leading to the creation of these future cancer-fighting immunotherapies. It includes essays by leading researchers that cover a wide variety of topics including T cell and non-T cell therapy, monoclonal antibody therapy, dendritic cell-based cancer vaccines, mesenchymal stromal cells, negative regulators in cancer immunology and immunotherapy, non-cellular aspects of cancer immunotherapy, the combining of cancer vaccines with conventional therapies, the combining of oncolytic viruses with cancer immunotherapy, transplantation, and more. The field of immunotherapy holds great promise that will soon come to fruition if creative investigators can bridge seemingly disparate disciplines, such as T cell therapy, gene therapy, and transplantation therapy. This text is a vital tool in the building of that bridge.

General Principles of Tumor Immunotherapy
General Principles of Tumor Immunotherapy

Author: Howard L. Kaufman

Publisher: Springer Science & Business Media

Published: 2007-10-12

Total Pages: 502

ISBN-13: 1402060874

DOWNLOAD EBOOK

This book brings together the world’s leading authorities on tumor immunology. This book describes the basic immunology principles that form the foundation of understanding how the immune system recognizes and rejects tumor cells. The role of the innate and adaptive immune responses is discussed and the implications of these responses for the design of clinical strategies to combat cancer are illustrated.

Cancer Vaccines and Immunotherapy
Cancer Vaccines and Immunotherapy

Author: Peter L. Stern

Publisher: Cambridge University Press

Published: 2000-08-17

Total Pages: 304

ISBN-13: 9780521622639

DOWNLOAD EBOOK

Rapid progress in the definition of tumor antigens, and improved immunization methods, bring effective cancer vaccines within reach. In this wide-ranging survey, leading clinicians and scientists review therapeutic cancer vaccine strategies against a variety of diseases and molecular targets. Intended for an interdisciplinary readership, their contributions cover the rationale, development, and implementation of vaccines in human cancer treatment, with specific reference to cancer of the cervix, breast, colon, bladder, and prostate, and to melanoma and lymphoma. They review target identification, delivery vectors and clinical trial design. The book begins and ends with lucid overviews from the editors, that discuss the most recent developments.

Patient Derived Tumor Xenograft Models
Patient Derived Tumor Xenograft Models

Author: Rajesh K. Uthamanthil

Publisher: Academic Press

Published: 2016-10-25

Total Pages: 0

ISBN-13: 9780128040102

DOWNLOAD EBOOK

Patient Derived Tumor Xenograft Models: Promise, Potential and Practice offers guidance on how to conduct PDX modeling and trials, including how to know when these models are appropriate for use, and how the data should be interpreted through the selection of immunodeficient strains. In addition, proper methodologies suitable for growing different type of tumors, acquisition of pathology, genomic and other data about the tumor, potential pitfalls, and confounding background pathologies that occur in these models are also included, as is a discussion of the facilities and infrastructure required to operate a PDX laboratory.

Oncoimmunology
Oncoimmunology

Author: Laurence Zitvogel

Publisher: Springer

Published: 2017-12-13

Total Pages: 700

ISBN-13: 3319624318

DOWNLOAD EBOOK

In this book, leading experts in cancer immunotherapy join forces to provide a comprehensive guide that sets out the main principles of oncoimmunology and examines the latest advances and their implications for clinical practice, focusing in particular on drugs with FDA/EMA approvals and breakthrough status. The aim is to deliver a landmark educational tool that will serve as the definitive reference for MD and PhD students while also meeting the needs of established researchers and healthcare professionals. Immunotherapy-based approaches are now inducing long-lasting clinical responses across multiple histological types of neoplasia, in previously difficult-to-treat metastatic cancers. The future challenges for oncologists are to understand and exploit the cellular and molecular components of complex immune networks, to optimize combinatorial regimens, to avoid immune-related side effects, and to plan immunomonitoring studies for biomarker discovery. The editors hope that this book will guide future and established health professionals toward the effective application of cancer immunology and immunotherapy and contribute significantly to further progress in the field.

Cancer Immunology and Immunotherapy
Cancer Immunology and Immunotherapy

Author: Mansoor M. Amiji

Publisher: Elsevier

Published: 2021-08-27

Total Pages: 548

ISBN-13: 0128233974

DOWNLOAD EBOOK

Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy examines the challenges of delivering immuno-oncology therapies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited. Nanotechnology-based targeted delivery strategies could improve the delivery efficiency of IO agents as well as provide additional avenues for novel therapeutic and vaccination strategies. Additionally, a number of locally-administered immunogenic scaffolds and therapeutic strategies, such as the use of STING agonist, could benefit from rationally designed biomaterials and delivery approaches. Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side. Comprehensive treaty covering all aspects of immuno-oncology (IO) Novel strategies for delivery of IO therapeutics and vaccines Forecasting on the future of nanotechnology and drug delivery for IO

Translational Immunotherapy of Brain Tumors
Translational Immunotherapy of Brain Tumors

Author: John H. Sampson

Publisher: Academic Press

Published: 2017-02-06

Total Pages: 406

ISBN-13: 0128026251

DOWNLOAD EBOOK

Translational Immunotherapy of Brain Tumors gives researchers and practitioners an up-to-date and comprehensive overview of the field. Chapters include adoptive immunotherapy, immunosuppression, CAR therapy of brain tumors, and dendritic cell therapy for brain tumors. Very few agents have been shown to be efficacious in the treatment of malignant gliomas. Recently, there have been a number of studies demonstrating the potential success of immunotherapy for brain tumors. Immunotherapeutics are becoming the most frequent drugs to be used in cancer therapy. These new breakthroughs, now approved by the FDA, are a part of multiple phase III international trials and ongoing research in malignant glioma, meaning that the information in this cutting-edge book will be of great importance to practitioners and researchers alike. 2018 BMA Medical Book Awards Highly Commended in Oncology - Comprehensive overview, providing an update on immunology, translational immunotherapy, and clinical trials relating to malignant gliomas - Edited by a prominent neurosurgeon with contributions by leading researchers in the field - Ideal resource for researchers and practitioners interested in learning about mechanisms that use the immune system to treat brain tumors

Encyclopedia of Cancer
Encyclopedia of Cancer

Author: Manfred Schwab

Publisher: Springer Science & Business Media

Published: 2008-09-23

Total Pages: 3307

ISBN-13: 3540368477

DOWNLOAD EBOOK

This comprehensive encyclopedic reference provides rapid access to focused information on topics of cancer research for clinicians, research scientists and advanced students. Given the overwhelming success of the first edition, which appeared in 2001, and fast development in the different fields of cancer research, it has been decided to publish a second fully revised and expanded edition. With an A-Z format of over 7,000 entries, more than 1,000 contributing authors provide a complete reference to cancer. The merging of different basic and clinical scientific disciplines towards the common goal of fighting cancer makes such a comprehensive reference source all the more timely.

Bayesian Designs for Phase I-II Clinical Trials
Bayesian Designs for Phase I-II Clinical Trials

Author: Ying Yuan

Publisher: CRC Press

Published: 2017-12-19

Total Pages: 238

ISBN-13: 1315354225

DOWNLOAD EBOOK

Reliably optimizing a new treatment in humans is a critical first step in clinical evaluation since choosing a suboptimal dose or schedule may lead to failure in later trials. At the same time, if promising preclinical results do not translate into a real treatment advance, it is important to determine this quickly and terminate the clinical evaluation process to avoid wasting resources. Bayesian Designs for Phase I–II Clinical Trials describes how phase I–II designs can serve as a bridge or protective barrier between preclinical studies and large confirmatory clinical trials. It illustrates many of the severe drawbacks with conventional methods used for early-phase clinical trials and presents numerous Bayesian designs for human clinical trials of new experimental treatment regimes. Written by research leaders from the University of Texas MD Anderson Cancer Center, this book shows how Bayesian designs for early-phase clinical trials can explore, refine, and optimize new experimental treatments. It emphasizes the importance of basing decisions on both efficacy and toxicity.

Mathematical, Computational and Experimental T Cell Immunology
Mathematical, Computational and Experimental T Cell Immunology

Author: Carmen Molina-París

Publisher: Springer Nature

Published: 2021-01-04

Total Pages: 300

ISBN-13: 3030572048

DOWNLOAD EBOOK

Mathematical, statistical, and computational methods enable multi-disciplinary approaches that catalyse discovery. Together with experimental methods, they identify key hypotheses, define measurable observables and reconcile disparate results. This volume collects a representative sample of studies in T cell immunology that illustrate the benefits of modelling-experimental collaborations and which have proven valuable or even ground-breaking. Studies include thymic selection, T cell repertoire diversity, T cell homeostasis in health and disease, T cell-mediated immune responses, T cell memory, T cell signalling and analysis of flow cytometry data sets. Contributing authors are leading scientists in the area of experimental, computational, and mathematical immunology. Each chapter includes state-of-the-art and pedagogical content, making this book accessible to readers with limited experience in T cell immunology and/or mathematical and computational modelling.